Cyxone Ab Stock Current Liabilities
| CYXO Stock | SEK 0.03 0.01 21.57% |
Cyxone AB fundamentals help investors to digest information that contributes to Cyxone AB's financial success or failures. It also enables traders to predict the movement of Cyxone Stock. The fundamental analysis module provides a way to measure Cyxone AB's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cyxone AB stock.
Cyxone |
Cyxone AB Company Current Liabilities Analysis
Cyxone AB's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
In accordance with the recently published financial statements, Cyxone AB has a Current Liabilities of 0.0. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The current liabilities for all Sweden stocks is 100.0% higher than that of the company.
Did you try this?
Run Positions Ratings Now
Positions RatingsDetermine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |
| All Next | Launch Module |
Cyxone Fundamentals
| Return On Equity | -1.07 | |||
| Return On Asset | -0.59 | |||
| Current Valuation | 7.74 M | |||
| Shares Outstanding | 98.44 M | |||
| Shares Owned By Insiders | 25.38 % | |||
| Price To Book | 1.00 X | |||
| Price To Sales | 5,168 X | |||
| EBITDA | (43.23 M) | |||
| Net Income | (45.03 M) | |||
| Cash And Equivalents | 56.34 M | |||
| Cash Per Share | 0.97 X | |||
| Current Ratio | 11.35 X | |||
| Book Value Per Share | 0.50 X | |||
| Cash Flow From Operations | (43.25 M) | |||
| Earnings Per Share | (0.76) X | |||
| Target Price | 4.2 | |||
| Beta | 0.54 | |||
| Market Capitalization | 52.96 M | |||
| Total Asset | 46.13 M | |||
| Net Asset | 46.13 M |
About Cyxone AB Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cyxone AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cyxone AB using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cyxone AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Cyxone Stock Analysis
When running Cyxone AB's price analysis, check to measure Cyxone AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyxone AB is operating at the current time. Most of Cyxone AB's value examination focuses on studying past and present price action to predict the probability of Cyxone AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyxone AB's price. Additionally, you may evaluate how the addition of Cyxone AB to your portfolios can decrease your overall portfolio volatility.